| Literature DB >> 10547427 |
Y Nishimura1, A Kamei, S Uno-Furuta, S Tamaki, G Kim, Y Adachi, K Kuribayashi, Y Matsuura, T Miyamura, Y Yasutomi.
Abstract
Recent studies have raised the possibility that DNA-based vaccination may prove useful for generating virus-specific cytotoxic T-lymphocytes (CTL) responses. Recently, a plasmid containing the human elongation factor 1alpha(EF1-alpha) promoter, pEF321, was reported to be a versatile expression vector for gene expression in mammalian cells in vitro. In the present study, we assessed the capability of a novel plasmid, pEFCE1E2, encoding hepatitis C virus (HCV) structural proteins (core, E1 and E2) under the EF1-alpha promoter to generate CTL against HCV in vivo. BALB/c mice were immunized with the pEFCE1E2 but not with a plasmid possessing the same cDNA under the cytomegalovirus developed HCV-specific effector cells by a single immunization. These effector cells elicited by pEFCE1E2 immunization were CD8(+) and major histocompatibility complex class I restricted. These studies provided evidence for the potential utility of the EF1-alpha promoter for development of DNA vaccines against HCV infections.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10547427 DOI: 10.1016/s0264-410x(99)00270-4
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641